Jan M. Rothman
Expertise in
48
conditions

Dr. Jan M. Rothman

Hematology Oncology
2500 West 12th Street, 
Erie, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
48
conditions
2500 West 12th Street, 
Erie, PA 

Overview

Jan M. Rothman, MD, is a medical oncologist and treats all medical oncology and hematology cases.

Dr. Rothman is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Bone Marrow Aspiration.

Dr. Rothman is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 5 clinical trials. Dr. Rothman is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine
American Board Of Internal Medicine

Fellowships

Winthrop University Hospital

Hospital Affiliations

Meadville Medical Center
Upmc Hamot
Upmc Chautauqua At Wca
Upmc Kane

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center - Erie
2500 West 12th Street, Erie, PA 16505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 4 Less Clinical Trials

3 Total Publications

Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Journal: JAMA oncology
Published: June 27, 2024
Similar Doctors
Expertise in
52
conditions
Dr. David J. Seastone
Hematology Oncology
Expertise in
52
conditions
Dr. David J. Seastone
Hematology Oncology
Referral may be required
Before you request

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (0.1 miles away)
814-836-2600
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David James Seastone, DO, PhD, is a medical oncologist and treats all medical oncology and hematology cases. Dr. Seastone is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Seastone is board certified in American Board Of Internal Medicine. Dr. Seastone is currently accepting new patients.

Expertise in
23
conditions
Dr. James P. Ohr
Hematology Oncology
Expertise in
23
conditions
Dr. James P. Ohr
Hematology Oncology
Referral may be required
Before you request

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (0.1 miles away)
814-836-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James P. Ohr, DO, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. He has a clinical interest in gastrointestinal malignancies, peritoneal carcinomas, and head and neck malignancies. Dr. Ohr is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Throat Cancer, Laryngeal Cancer, Pleuropulmonary Blastoma, Oral Squamous Cell Carcinoma, and Gastrostomy. Dr. Ohr is board certified in American Board Of Internal Medicine. Dr. Ohr is currently accepting new patients.

Expertise in
24
conditions
Dr. Zulfiqar Hussain
Hematology Oncology
Expertise in
24
conditions
Dr. Zulfiqar Hussain
Hematology Oncology
Referral may be required
Before you request

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (0.1 miles away)
814-836-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Zulfiqar Hussain, MD, FACP is a medical oncologist and treats all hematology cases and solid malignancies. Dr. Hussain is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Thrombocytopenia. Dr. Hussain is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Hussain is currently accepting new patients.

Frequently Asked Questions about Dr. Jan M. Rothman

How do I make an appointment with Dr. Jan M. Rothman?

You can book an appointment with Dr. Jan M. Rothman by calling their office at 814-836-2600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jan M. Rothman a top-rated expert for Mantle Cell Lymphoma (MCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jan M. Rothman is classified as an Distinguished expert for Mantle Cell Lymphoma (MCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jan M. Rothman specialize in?

While Dr. Jan M. Rothman is a Hematology Oncology, they have specific expertise in Mantle Cell Lymphoma (MCL), Lung Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Jan M. Rothman participate in research or clinical trials?

Yes. Dr. Jan M. Rothman has published 3 articles and abstracts on conditions like Mantle Cell Lymphoma (MCL). You can view a list of Dr. Jan M. Rothman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jan M. Rothman accept my insurance?

Dr. Jan M. Rothman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 814-836-2600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rothman's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 35 Advanced Conditions
    View All 106 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile